Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency
NCT02574910Phase 1Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abiraterone in congenital adrenal hyperplasia (CAH) (3 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Normalization of Serum Androstenedione Level at 7 days. Started Aug 2017; status: terminated.
02
Drugs
abiraterone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT02574910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574910.